文献速递胸部肿瘤放疗放疗物理与技术

间质性肺病早期肺癌:立体定向消融放疗与手术结局

Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease.
PubMed 文献 · Radiother Oncol · 2026-05-09

该单中心回顾性研究纳入67例经ILD多学科小组评估的I-II期肺癌合并间质性肺病患者,比较手术(n=33)与SABR(n=34)的疗效与安全性。IPTW校正后两组PFS(HR 1.18)与OS(HR 0.94)均无显著差异,肺不良事件发生率无显著差异,进行性肺纤维化与更差PFS和OS独立相关。

要点

  • IPTW校正后手术与SABR的PFS和OS均无显著差异。
  • 肺不良事件总体发生率21%,两组间无显著差异。
  • 进行性肺纤维化是PFS和OS更差的独立预后因素。

核心结论

  • SABR与手术均为合并间质性肺病的早期肺癌患者可行的根治性选择。
  • 潜在毒性风险可接受,间质性肺病诊断不应妨碍该人群接受根治性治疗。

研究设计与样本

  • 单中心回顾性研究,纳入2006-2024年经间质性肺病小组常规治疗前评估后接受SABR或手术的I-II期肺癌合并间质性肺病患者67例(手术33例,SABR 34例)。
  • 主要终点为无进展生存期和总生存期,采用未校正和逆概率治疗加权(IPTW)分析;次要终点包括预后因素和肺不良事件。

主要发现

  • 手术组2年PFS为54%,SABR组为53%;2年OS分别为68%和56%。
  • IPTW校正后,手术与SABR的PFS无显著差异(HR 1.18,95%CI 0.48-2.90;p=0.710),OS亦无显著差异(HR 0.94,95%CI 0.38-2.31;p=0.890)。
  • 进行性肺纤维化与更差PFS和OS独立相关。

临床怎么用

  • 对经间质性肺病多学科评估的I-II期肺癌合并间质性肺病患者,SABR和手术均可考虑为根治性治疗选项。
  • 治疗决策时需关注进行性肺纤维化,其与更差生存相关。

局限性

  • 回顾性研究,样本量有限(67例),可能存在选择偏倚。
  • 手术组患者一般更年轻且WHO体能状态更好,尽管采用IPTW校正,仍不能排除残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: /objective(s): The ASPIRE-ILD (n = 39) and WJOG-6711 L (n = 39) studies suggest both stereotactic ablative radiotherapy (SABR) and surgery might be feasible and safe for selected patients with early-stage NSCLC and interstitial lung disease (ILD). Real-world data on patient outcomes is limited. We analyzed outcomes of SABR and surgery in ILD-lung cancer patients managed at a referral center. MATERIALS: /Methods: We retrospectively studied ILD patients with stage I-II lung cancer treated with SABR or surgery (2006-2024) after routine pre-treatment review by an ILD panel. Primary outcomes were progression-free survival (PFS) and overall survival (OS), analyzed both using unadjusted and inverse probability for treatment weighting (IPTW) analyses. Secondary endpoints included prognostic factors and pulmonary adverse events. RESULTS: A total of 67 ILD-lung cancer patients with stage I-II disease underwent surgery (n = 33) or SABR (n = 34). Surgical patients were generally younger with better WHO performance status. Two-year PFS after surgery was 54% and 53% after SABR; two-year OS was 68% and 56%, respectively. After IPTW adjustment, no significant differences were observed between surgery and SABR for PFS (HR 1.18, 95%CI: 0.48-2.90; p = 0.710) or OS (HR 0.94, 95%CI: 0.38-2.31; p = 0.890). Sixteen pulmonary adverse events occurred in 21% (n = 14) of all patients, including ILD exacerbations (n = 3), surgical complications (n = 6), and radiation pneumonitis (n = 7), with no significant differences between treatments. Progressive pulmonary fibrosis was independently associated with worse PFS and OS. CONCLUSION: SABR and surgery are feasible curative options for ILD patients with early-stage lung cancer. As potential toxicity risks appear acceptable, the diagnosis should not preclude curative treatments in this population.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tomassen ML, Nijman SFM, Nossent EJ, et al. Outcomes of stereotactic ablative radiotherapy or surgery for early-stage lung cancer in patients with interstitial lung disease. Radiother Oncol. 2026. PMID: 42114598. doi:10.1016/j.radonc.2026.111588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。